WebMay 23, 2024 · Review of the topline phase I data shows that KL1333 has a highly favourable and very clear dose-proportional pharmacokinetic (PK) profile. ... "We are very excited about the results from the first in human clinical trial of KL1333 and see them as clearly promising for the continued clinical development of this important program … WebJan 17, 2024 · KL1333 is a modulator of the cellular levels of NAD+, a central co-enzyme in the cell’s energy metabolism. It has been shown to increase mitochondrial energy output, reduce lactate accumulation, lower the formation of harmful free radicals, and have long-term benefits on energy metabolism, such as the formation of new mitochondria.
Abliva reports completion of KL1333 Phase 1a/b study
WebMay 25, 2024 · NeuroVive Pharmaceutical AB and Yungjin Pharm announced positive topline results from a Phase 1 clinical trial evaluating KL1333, an investigational treatment for genetic mitochondrial diseases. The randomized, single ascending dose trial (NCT03056209) was designed to investigate the pharmacokinetics (drug movement … WebDec 20, 2024 · LUND, Sweden, Dec. 20, 2024 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the completed recruitment of healthy volunteers in the second part of the company's ongoing Phase Ia/b clinical study with candidate drug KL1333, in development for chronic oral treatment of primary … contact lenses not as good as glasses
Efficacy of KL1333 in Adult Patients With Primary …
WebA Clinical Phase II Efficacy Study of KL1333 for the Treatment of Primary Mitochondrial Diseases Status: Planning Phase of Trial: Phase II Latest Information Update: 10 Jul 2024 … WebMar 19, 2024 · KL1333 is currently being evaluated in clinical phase I studies and has been granted orphan drug designation in both the United States and Europe. KL1333 has been … WebJun 1, 2024 · Progression of the KL1333 Phase 2/3 trial to an interim analysis of the first 40 patients in late 2024/early 2024 which will inform as to the size required for the second part of the study and provide insight into the relative chance of overall success; Support non-clinical activities NV354 program (5% of the proceeds): eedition the state south carolina